Detalhe da pesquisa
1.
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol
; 186: 182-190, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38718741
2.
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol
; 187: 128-138, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38833992
3.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol
; 184: 168-177, 2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38325276
4.
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial).
Int J Gynecol Cancer
; 34(6): 942-945, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38479803
5.
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Cancer
; 129(12): 1846-1855, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37060236
6.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37862791
7.
Safety and management of niraparib monotherapy in ovarian cancer clinical trials.
Int J Gynecol Cancer
; 33(6): 971-981, 2023 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36792166
8.
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
Int J Gynecol Cancer
; 33(6): 929-936, 2023 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36759001
9.
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.
Int J Gynecol Cancer
; 33(11): 1733-1742, 2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931976
10.
Outcomes and endpoints of relevance in gynecologic cancer clinical trials.
Int J Gynecol Cancer
; 33(3): 323-332, 2023 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878559
11.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer
; 33(4): 562-570, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564099
12.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Lancet Oncol
; 23(8): e374-e384, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901833
13.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med
; 381(25): 2416-2428, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31851799
14.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med
; 381(25): 2391-2402, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562799
15.
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
BMC Cancer
; 22(1): 1150, 2022 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36348385
16.
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Gynecol Oncol
; 164(2): 254-264, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34952708
17.
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
Gynecol Oncol
; 166(3): 494-502, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35851489
18.
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Gynecol Oncol
; 166(1): 36-43, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550709
19.
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context.
Future Oncol
; 18(23): 2505-2536, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35791804
20.
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study).
Future Oncol
; 18(31): 3481-3492, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066851